Last reviewed · How we verify
Phase I Multicenter, Open-label, Dose-escalating Clinical and Pharmacokinetic Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of PM02734 administered in combination with erlotinib to determine the safety and tolerability and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the combination of PM02734 and erlotinib, in patients with advanced malignant solid tumors.
Details
| Lead sponsor | PharmaMar |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 35 |
| Start date | 2009-01 |
| Completion | 2011-06 |
Conditions
- Advanced Malignant Solid Tumors
Interventions
- PM02734 and erlotinib
- Erlotinib
Primary outcomes
- To determine the safety and tolerability and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the combination of PM02734 and erlotinib — 2 years
Countries
United States, Spain